Annuncio pubblicitario
Italia markets closed
  • FTSE MIB

    34.249,77
    +310,02 (+0,91%)
     
  • Dow Jones

    38.239,66
    +153,86 (+0,40%)
     
  • Nasdaq

    15.927,90
    +316,14 (+2,03%)
     
  • Nikkei 225

    37.934,76
    +306,28 (+0,81%)
     
  • Petrolio

    83,66
    +0,09 (+0,11%)
     
  • Bitcoin EUR

    58.934,01
    -960,86 (-1,60%)
     
  • CMC Crypto 200

    1.304,48
    -92,06 (-6,59%)
     
  • Oro

    2.349,60
    +7,10 (+0,30%)
     
  • EUR/USD

    1,0699
    -0,0034 (-0,32%)
     
  • S&P 500

    5.099,96
    +51,54 (+1,02%)
     
  • HANG SENG

    17.651,15
    +366,61 (+2,12%)
     
  • Euro Stoxx 50

    5.006,85
    +67,84 (+1,37%)
     
  • EUR/GBP

    0,8558
    -0,0015 (-0,18%)
     
  • EUR/CHF

    0,9770
    -0,0015 (-0,15%)
     
  • EUR/CAD

    1,4617
    -0,0032 (-0,22%)
     

Where Will Vaxart Be in 1 Year?

Where Will Vaxart Be in 1 Year?

Vaxart (NASDAQ: VXRT) has a plan to address the challenge, but a recent phase 1 readout crushed the stock. When Vaxart released the preliminary data from its phase 1 trial for VXA-CoV2-1, the company's oral COVID-19 tablet vaccine candidate, the headline of the press release touted positive results. Management went so far as to express increased confidence in the drug and in the tablet vaccine platform overall.